Atrial Cardiomyocytes

Human iPSC-derived atrial-like cardiomyocytes

Human-induced pluripotent stem cell (iPSC) derived atrial cardiomyocytes are a powerful tool to improve in vitro testing of new treatments for atrial arrhythmias. Our team can manufacture atrial cardiomyocytes at the scale needed from the iPSC that best fits your project, ensuring high purity and consistency between batches. Custom assays can be developed based on this model to support your large screenings with minimal variability.

cardiac

cTNT (green) and the atrial specific marker
COUP-TFII (red). Nuclear staining (blue)

Cellular Identity Physiologically Relevant Highly suitable for electrophysiological research

Atrial cardiomyocytes generated on-demand are characterized by flow cytometry to ensure a high purity of atrial-like cardiomyocytes, assessing double expression of cardiac Troponin T (cTNT) and the transcription factor COUPII (COUP-TFII). They typically present an atrial-like genetic profile as shown by RNA-seq data looking at atrial/ventricular fold expression.

FACS analysis of a representative batch of Ncardia Atrial Cardiomyocytes showing 95,5% expresion of cardiac TNT and 84% of atrial-like cells with double expression of cardiac TNT and the atrial marker COUPTFII.

Immunofluorescence staining of Ncardia Atrial Cardiomyocytes showing double expression of cardia TNT (green) and the specific atrial marker COUP-TFII (red).

Atrial cardiomyocytes generated on-demand show atrial-like action potential shape and high electrical activity as measured by MEA analysis. They have a stable beat rate with very low inter- and intra-well variation. This model is, therefore, physiologically relevant for the phenotypic study of atrial diseases. Our expert scientists can develop and execute tailor assays to support your drug discovery research in the cardiac field.

High electrical activity of human iPSC-derived atrial cardiomyocytes at 10 days post-seeding

Atrial cardiomyocytes generated on-demand are suitable for electrophysiological research and drug discovery. They show relevant pharmacological responses to known cardioactive compounds with acute and chronic treatments. Our scientists develop and optimize tailor assays to test the effect and safety of new therapeutic candidates in this model and provide relevant predictions to help you advance your campaigns.

Concentration-dependent increase in FPD and decrease in depolarization peak amplitude after treatment with Vernakalant (multi-channel blocker)

Chronic drug-induced cardiotoxicity: concentration- and time-dependent decrease of depolarization peak amplitudes and number of active electrodes after treatment with Doxorubicin